Nature reports a rather scary story. It is an item of news that many have known was coming … bacteria have now become resistant to the powerful carbapenem antibiotics — one of the last drugs left on the shelf.
The agency heads were talking about the soaring increase in a little-known class of antibiotic-resistant bacteria: carbapenem-resistant Enterobacteriaceae (CREs). Davies, the United Kingdom’s chief medical officer, described CREs as a risk as serious as terrorism (see Nature 495, 141; 2013). “We have a very serious problem, and we need to sound an alarm,” said Frieden, director of the US Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia.
Their dire phrasing was warranted. CREs cause bladder, lung and blood infections that can spiral into life-threatening septic shock. They evade the action of almost all antibiotics — including the carbapenems, which are considered drugs of last resort — and they kill up to half of all patients who contract them. In the United States, these bacteria have been found in 4% of all hospitals and 18% of those that offer long-term critical care. And an analysis carried out in the United Kingdom predicts that if antibiotics become ineffective, everyday operations such as hip replacements could end in death for as many as one in six
Some might argue that it will never get that bad, but alas, there will be no new drugs available soon.
Basically because of the rapid advance of resistance. When you have something that works, you use it sparingly to ensure it continues to be effective for as long as possible. As a consequence this low level of usage means that it is not very profitable to the pharmaceutical companies and so the development of new antibiotics is simply not worth the investment they would need to deploy.
Now that is the truly scary bit.